Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has reached a significant milestone in its clinical development pipeline, completing patient enrollment in APPROACH, its Phase 3 pivotal study evaluating HLP003 for major depressive disorder (MDD). The company anticipates topline data from this trial in the fourth quarter of 2026, a critical step toward potentially bringing a novel serotonergic agonist (NSA) to market. This announcement, made alongside the company's financial results for the quarter ended June 30, 2026, underscores Helus Pharma's commitment to addressing the large unmet need in mental health treatment.
The APPROACH study is part of the broader PARADIGM program, which includes EMBRACE, a second pivotal Phase 3 trial where enrollment is already underway. Additionally, participants from earlier studies continue to roll over into EXTEND, a long-term extension study. These trials are designed to evaluate HLP003 as an adjunctive treatment for MDD, a condition affecting millions worldwide. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer significant improvement over existing therapies.
Beyond HLP003, Helus Pharma is advancing HLP004 for generalized anxiety disorder (GAD). Following Phase 2 results that demonstrated statistically significant and clinically meaningful improvements from baseline, the company expects to complete the design of the next study by the end of the third quarter of 2026. This progress reflects the company's broader strategy of developing a pipeline of NSA candidates targeting various mental health conditions.
Financially, Helus Pharma reported cash and cash equivalents of $166.4 million as of June 30, 2026. The company reported a net loss of $47.8 million for the quarter, compared to $24.6 million in the same period last year, with cash-based operating expenses increasing to $37.5 million from $23.9 million. The rise in expenses is attributed to the continued advancement of the Phase 3 trials for HLP003, including APPROACH, EMBRACE, and EXTEND. Additionally, the company is progressing HLP005 toward candidate selection, with a viable development candidate anticipated in the second half of 2027.
The completion of enrollment in APPROACH is a pivotal step for Helus Pharma. If the trial meets its endpoints, HLP003 could offer a new option for patients with MDD who have not responded adequately to standard treatments. The Breakthrough Therapy Designation underscores the potential of HLP003 to provide meaningful improvement over existing therapies, and the ongoing Phase 3 program is designed to confirm its efficacy and safety profile.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists. These synthetic molecules are designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit Helus Pharma or follow the company on social media platforms. The latest news and updates are available in the company's newsroom at https://ibn.fm/HELP.
The advancement of HLP003 and HLP004 reflects Helus Pharma's dedication to addressing mental health conditions with high unmet needs. With a robust financial position and a clear development timeline, the company is poised to make significant contributions to the field of psychiatry. The expected topline data in Q4 2026 will be a key catalyst, potentially reshaping the treatment landscape for major depressive disorder.
